Supplementary Figure S5 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models

2026 Open access

Read full text
Authors: Dejan Juric, Kyung Song, Radia Marie Johnson, Melissa Kate Accordino, Philippe Lucien Bedard, Andrés Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira
+34 more Cristina Saura, Peter Schmid, Nicholas C. Turner, Andreea Varga, Steven B. Gendreau, Michael S.H. Hwang, Zheng Kuang, Jeffrey Lau, Eva Lin, Trang Pham, Danilo Maddalo, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Scott E. Martin, Nicole M. Sodir, Ethan S. Sokol, Zachary J. Whitfield, Alice Wong, Robert L. Yauch, Junko Aimi, Sravanthi Cheeti, Jill O. Fredrickson, Stephanie Hilz, Marc A. Hafner, Katherine E. Hutchinson, Yanling Jin, Ubong Peters, Daniel Zingg, Stephanie Royer‐Joo, Noopur Shankar, Jennifer L. Schutzman, Komal L. Jhaveri, Anwesha Dey
DOI: 10.1158/1078-0432.31006732
Cited by: 0

Abstract

Effect of FGFR2-selective inhibitor and non-selective inhibitor infigratinib on normalized growth and downstream FGFR signaling

Fields of Study & Subjects

Fibroblast Growth Factor Research PI3K/AKT/mTOR signaling in cancer Sympathectomy and Hyperhidrosis Treatments

Publication details

Publication date
6 January 2026